Next-generation probiotics as a therapeutic strategy for the treatment of phenylketonuria: a review

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorGoiano Fed Inst Educ Sci & Technol-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorOliveira Filho, Josemar Goncalves de-
Autor(es): dc.creatorCarvalho, Adriana Sousa e Silva-
Autor(es): dc.creatorAlves, Jordana dos Santos-
Autor(es): dc.creatorEgea, Mariana Buranelo-
Data de aceite: dc.date.accessioned2025-08-21T22:48:36Z-
Data de disponibilização: dc.date.available2025-08-21T22:48:36Z-
Data de envio: dc.date.issued2022-11-29-
Data de envio: dc.date.issued2022-11-29-
Data de envio: dc.date.issued2022-05-12-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1093/nutrit/nuac024-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/237560-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/237560-
Descrição: dc.descriptionPhenylketonuria (PKU) is a rare genetic disease that causes brain toxicity due to the inability of the body to convert dietary phenylalanine to tyrosine by the action of phenylalanine hydroxylase. The only treatment for PKU so far is lifelong dietary intervention to ensure normal human growth and neurodevelopment. However, in adults, low long-term adherence to this type of dietary intervention has been observed. Given the important role of the intestinal microbiota in the process of digestion and disease prevention, probiotics could be a therapeutic strategy to help degrade dietary phenylalanine, reducing its levels before ingestion. Genetically modified probiotics designed as live biotherapeutic agents for the treatment of specific diseases are sophisticated alternative therapeutic strategies. In this review, the focus is on demonstrating what has been elucidated so far about the use of next-generation probiotics as a therapeutic strategy in the treatment of individuals with PKU. The results described in the literature are encouraging and use genetically modified engineered probiotics showing efficacy both in vitro and in vivo. These probiotics appear to be suitable for meeting the unmet need for new drugs for PKU.-
Descrição: dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)-
Descrição: dc.descriptionFundacao de Amparo a Pesquisa do Estado de Goias-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionInstituto Federal Goiano-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionGoiano Fed Inst Educ Sci & Technol, Campus Rio Verde,Rod Sul Goiana,Km 01, BR-75901970 Rio Verde, Go, Brazil-
Descrição: dc.descriptionSao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP, Brazil-
Descrição: dc.descriptionSao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP, Brazil-
Descrição: dc.descriptionCAPES: 001-
Descrição: dc.descriptionCNPq: 308489/2020-9-
Descrição: dc.descriptionInstituto Federal Goiano: 23218.002598.2021-64-
Formato: dc.format2100-2112-
Idioma: dc.languageen-
Publicador: dc.publisherOxford Univ Press Inc-
Relação: dc.relationNutrition Reviews-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectEngineered probiotics-
Palavras-chave: dc.subjectEscherichia coli Nissle-
Palavras-chave: dc.subjectPhenylalanine hydroxylase-
Palavras-chave: dc.subjectPKU-
Título: dc.titleNext-generation probiotics as a therapeutic strategy for the treatment of phenylketonuria: a review-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.